NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and
Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the
Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026 Presented updated data at ASCO 2026 demonstrating
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard
Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, Gamma-Delta T cell Engagers, CAR-Gamma-Delta T Cells and Cytokine-Armored Cells NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc.
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma Translational data combines advanced artificial intelligence (AI), immunogenomics,
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical